{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:30:47Z","timestamp":1790101847678,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s43440-025-00762-1","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:04:45Z","timestamp":1752815085000},"page":"1364-1373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early plasma changes of HIF-1 alpha, matrix metalloproteinases-2 and \u2212\u20099, and tissue inhibitor of matrix metalloproteinase-1 in patients with infantile hemangiomas treated with propranolol"],"prefix":"10.1007","volume":"77","author":[{"given":"Ma\u0142gorzata","family":"Kowalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Martyna","family":"Koper-Lenkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"D\u0119bek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hermanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Matuszczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"762_CR1","doi-asserted-by":"publisher","unstructured":"Kunimoto K, Yamamoto Y, Jinnin M. ISSVA classification of vascular anomalies and molecular biology. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23042358.","DOI":"10.3390\/ijms23042358"},{"key":"762_CR2","doi-asserted-by":"crossref","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017:85\u201394.","DOI":"10.1016\/S0140-6736(16)00645-0"},{"key":"762_CR3","doi-asserted-by":"publisher","unstructured":"Buckmiller LM. Update on hemangiomas and vascular malformations. Curr Opin Otolaryngol Head Neck Surg. 2004;12. https:\/\/doi.org\/10.1097\/01.moo.0000145946.67222.01.","DOI":"10.1097\/01.moo.0000145946.67222.01"},{"key":"762_CR4","doi-asserted-by":"publisher","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Hubiche T, Boralevi F, Thambo J-B, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358. https:\/\/doi.org\/10.1056\/nejmc0708819","DOI":"10.1056\/nejmc0708819"},{"key":"762_CR5","doi-asserted-by":"publisher","unstructured":"Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09848.x.","DOI":"10.1111\/j.1365-2133.2010.09848.x"},{"key":"762_CR6","doi-asserted-by":"publisher","unstructured":"Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. JDDG: J Der Deutschen Dermatologischen Gesellschaft. 2017;15. https:\/\/doi.org\/10.1111\/ddg.13365","DOI":"10.1111\/ddg.13365"},{"key":"762_CR7","doi-asserted-by":"publisher","unstructured":"Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015;100. https:\/\/doi.org\/10.1136\/archdischild-2014-306197.","DOI":"10.1136\/archdischild-2014-306197"},{"key":"762_CR8","doi-asserted-by":"publisher","unstructured":"Masoud GN, Li W. HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5. https:\/\/doi.org\/10.1016\/j.apsb.2015.05.007.","DOI":"10.1016\/j.apsb.2015.05.007"},{"key":"762_CR9","doi-asserted-by":"publisher","unstructured":"Mihm MC, Nelson JS, Hypothesis. The metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol. 2010;37. https:\/\/doi.org\/10.1111\/j.1600-0560.2010.01521.x.","DOI":"10.1111\/j.1600-0560.2010.01521.x"},{"key":"762_CR10","doi-asserted-by":"publisher","unstructured":"Kowalska M, D\u0119bek W, Matuszczak E. Infantile hemangiomas: an update on pathogenesis and treatment. J Clin Med. 2021;10. https:\/\/doi.org\/10.3390\/jcm10204631.","DOI":"10.3390\/jcm10204631"},{"key":"762_CR11","doi-asserted-by":"publisher","unstructured":"Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009;21. https:\/\/doi.org\/10.3892\/or_00000358.","DOI":"10.3892\/or_00000358"},{"key":"762_CR12","doi-asserted-by":"publisher","unstructured":"Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69. https:\/\/doi.org\/10.1097\/00006534-198203000-00002.","DOI":"10.1097\/00006534-198203000-00002"},{"key":"762_CR13","doi-asserted-by":"publisher","unstructured":"Annabi B, Lachambre MP, Plouffe K, Moumdjian R, B\u00e9liveau R. Propranolol adrenergic Blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 2009;60. https:\/\/doi.org\/10.1016\/j.phrs.2009.05.005.","DOI":"10.1016\/j.phrs.2009.05.005"},{"key":"762_CR14","doi-asserted-by":"publisher","unstructured":"Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1698","DOI":"10.1158\/1078-0432.CCR-05-1698"},{"key":"762_CR15","doi-asserted-by":"publisher","unstructured":"Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2496.","DOI":"10.1158\/0008-5472.CAN-06-2496"},{"key":"762_CR16","doi-asserted-by":"publisher","unstructured":"Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20. https:\/\/doi.org\/10.1016\/j.semcancer.2010.05.002.","DOI":"10.1016\/j.semcancer.2010.05.002"},{"key":"762_CR17","doi-asserted-by":"publisher","unstructured":"Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, et al. Hypoxia-induced mediators of stem\/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007;27. https:\/\/doi.org\/10.1161\/ATVBAHA.107.150284.","DOI":"10.1161\/ATVBAHA.107.150284"},{"key":"762_CR18","doi-asserted-by":"publisher","unstructured":"Yin RR, Hao D, Chen P. Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma. Eur Rev Med Pharmacol Sci. 2018;22. https:\/\/doi.org\/10.26355\/EURREV_201808_15615.","DOI":"10.26355\/EURREV_201808_15615"},{"key":"762_CR19","doi-asserted-by":"publisher","unstructured":"Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93. https:\/\/doi.org\/10.1172\/JCI117241.","DOI":"10.1172\/JCI117241"},{"key":"762_CR20","doi-asserted-by":"publisher","unstructured":"Park M, Jung HL, Shim YJ, Kim HS, Yoon HS, Park SK, et al. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. Pediatr Res. 2020;88. https:\/\/doi.org\/10.1038\/s41390-020-0862-1.","DOI":"10.1038\/s41390-020-0862-1"},{"key":"762_CR21","doi-asserted-by":"publisher","unstructured":"Li P, Guo Z, Gao Y, Pan W. Propranolol represses infantile hemangioma cell growth through the \u03b22-adrenergic receptor in a HIF-1\u03b1-dependent manner. Oncol Rep. 2015;33. https:\/\/doi.org\/10.3892\/or.2015.3911.","DOI":"10.3892\/or.2015.3911"},{"key":"762_CR22","doi-asserted-by":"publisher","unstructured":"Xia HF, Zhu JY, Wang JN, Ren JG, Cai Y, Wang FQ, et al. Association of ATF4 expression with tissue hypoxia and M2 macrophage infiltration in infantile hemangioma. J Histochem Cytochem. 2017;65. https:\/\/doi.org\/10.1369\/0022155417694872.","DOI":"10.1369\/0022155417694872"},{"key":"762_CR23","doi-asserted-by":"publisher","unstructured":"Chen YZ, Bai N, Bi JH, Liu XW, Xu GQ, Zhang LF et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1\u03b1 dependent mechanisms. Braz J Med Biol Res. 2017;50. https:\/\/doi.org\/10.1590\/1414-431x20176138","DOI":"10.1590\/1414-431x20176138"},{"key":"762_CR24","doi-asserted-by":"publisher","unstructured":"Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK. Propranolol induces regression of hemangioma cells through HIF-1\u03b1-mediated Inhibition of VEGF-A. Ann Surg. 2012;256. https:\/\/doi.org\/10.1097\/SLA.0b013e318254ce7a","DOI":"10.1097\/SLA.0b013e318254ce7a"},{"key":"762_CR25","doi-asserted-by":"publisher","unstructured":"Gomez-Acevedo H, Dai Y, Strub G, Shawber C, Wu JK, Richter GT. Identification of putative biomarkers for infantile hemangiomas and propranolol treatment via data integration. Sci Rep. 2020;10. https:\/\/doi.org\/10.1038\/s41598-020-60025-2","DOI":"10.1038\/s41598-020-60025-2"},{"key":"762_CR26","doi-asserted-by":"publisher","unstructured":"Lorusso B, Cerasoli G, Falco A, Frati C, Graiani G, Madeddu D, et al. \u0392-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. Vascul Pharmacol. 2022;146. https:\/\/doi.org\/10.1016\/j.vph.2022.107110.","DOI":"10.1016\/j.vph.2022.107110"},{"key":"762_CR27","doi-asserted-by":"publisher","unstructured":"Lin Z, Wang L, Huang G, Wang W, Lin H. Propranolol inhibits the activity of PI3K, AKT, and HIF-1\u03b1 in infantile hemangiomas. Pediatr Surg Int. 2018;34. https:\/\/doi.org\/10.1007\/s00383-018-4347-9.","DOI":"10.1007\/s00383-018-4347-9"},{"key":"762_CR28","unstructured":"Yujuan T, Shaoquan C, Zaizhong Z, Shuming C, Guoliang H, Lie W. Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type. Zhonghua Zheng Xing Wai Ke Za Zhi. 2015;31."},{"key":"762_CR29","doi-asserted-by":"publisher","unstructured":"Wu S, Wang B, Chen L, Xiong S, Zhuang F, Huang X et al. Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9. Exp Ther Med. 2015;10. https:\/\/doi.org\/10.3892\/etm.2015.2650","DOI":"10.3892\/etm.2015.2650"},{"key":"762_CR30","doi-asserted-by":"publisher","unstructured":"Tani S, Kunimoto K, Inaba Y, Mikita N, Kaminaka C, Kanazawa N, et al. Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. Drug Discov Ther. 2020;14. https:\/\/doi.org\/10.5582\/ddt.2020.03014.","DOI":"10.5582\/ddt.2020.03014"},{"key":"762_CR31","doi-asserted-by":"publisher","unstructured":"Zhong S, Yang G, Xia C, Duanlian Z, Shan S. Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma. J Huazhong Univ Sci Technol - Med Sci. 2009;29. https:\/\/doi.org\/10.1007\/s11596-009-0516-3","DOI":"10.1007\/s11596-009-0516-3"},{"key":"762_CR32","doi-asserted-by":"publisher","unstructured":"Vergani V, Garofalo A, Bani MR, Borsotti P, Parker MP, Drudis T, et al. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer. 2001;91. https:\/\/doi.org\/10.1002\/1097-0215(200002)9999:9999%3C::AID-IJC1035%3E3.3.CO;2-G.","DOI":"10.1002\/1097-0215(200002)9999:9999%3C::AID-IJC1035%3E3.3.CO;2-G"},{"key":"762_CR33","doi-asserted-by":"publisher","unstructured":"Pandey A, Singh A, Ali W, Srivastava A, Gupta A, Kureel S, et al. Evaluation of effect of propranolol on serum vascular endothelial growth factor and tissue inhibitor of metalloproteinase-2 levels in infantile hemangioma. J Indian Assoc Pediatr Surg. 2020;25. https:\/\/doi.org\/10.4103\/jiaps.JIAPS_22_19.","DOI":"10.4103\/jiaps.JIAPS_22_19"},{"key":"762_CR34","doi-asserted-by":"publisher","unstructured":"Hermans MM, Rietman AB, Schappin R, de Laat PCJ, Mendels EJ, Breur JMPJ et al. Long-term neurocognitive functioning of children treated with propranolol or Atenolol for infantile hemangioma. Eur J Pediatr 2023;182. https:\/\/doi.org\/10.1007\/s00431-022-04674-7","DOI":"10.1007\/s00431-022-04674-7"},{"key":"762_CR35","doi-asserted-by":"publisher","unstructured":"Hermans MM, Pasmans SGMA, de Laat PCJ, Slieker MG, Mendels EJ, de Graaf M, et al. Propranolol or Atenolol for the management of infantile hemangioma: implications for long-term health. JAAD Int. 2023;11. https:\/\/doi.org\/10.1016\/j.jdin.2023.02.001.","DOI":"10.1016\/j.jdin.2023.02.001"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00762-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:07:16Z","timestamp":1758078436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00762-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00762-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}